DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations
Leadership Team Continues to Expand with Addition of Key Leader in Clinical OperationsMINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appoint...